Dako Denmark A/S : Dako to Collaborate with Pfizer on Companion Diagnostics

 Dako Denmark A/S : Dako to Collaborate with Pfizer on Companion Diagnostics

GLOSTRUP, Denmark, Feb. 12, 2013 - Dako, an Agilent Technologies company,
announced today it has entered into a collaboration agreement with Pfizer in
the field of companion diagnostics.

The agreement constitutes a legal framework for various collaboration
projects between the two companies, covering research, development and
commercialization as well as advisory services.

"We are extremely excited to partner with Pfizer, a company with such a global
presence and reputation for market leadership," said Lars Holmkvist, CEO of
Dako and senior vice president, Agilent. "This collaboration is testimony to
the level of expertise and service Dako is committed to delivering to our
partners in companion diagnostics."

Companion diagnostics are seen as the cornerstones of precision medicine. They
provide a way to improve patient care and reduce health-care costs by matching
specific therapies to the individuals most likely to benefit from them, since
all patients do not respond in the same way.

"This partnership with Dako will support Pfizer's companion diagnostics
efforts, an important component of our growing Precision Medicine
capabilities," said John Hubbard, senior vice president, Development
Operations at Pfizer. "Precision Medicine R&D is designed to advance more
targeted therapies for patients, improve efficacy, safety and success rates,
and expedite development."

Financial terms of the agreement were not disclosed.

Today's news follows an earlier announcement from Dako introducing a master
framework agreement between Dako and Eli Lilly and Company, which focuses on
developing novel companion diagnostics for Eli Lilly's oncology pipeline.

About Dako - An Agilent Technologies Company
Dako is relentless in its commitment to fighting cancer together with
customers and strategic partners-because patients' lives depend on companies
continuing to bring scientific advancement to the diagnostic and therapeutic
fields.

Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's reagents, instruments,
software and expertise to make accurate diagnoses and determine the most
effective treatment for cancer patients. Dako, with 1,200 employees, operates
in more than 100 countries. Dako became part of Agilent Technologies on June
21, 2012. Information about Dako is available at www.dako.com.

About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company's 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.

EDITORIAL CONTACT:

Maia Fredtoft Søchting
Communications
+45 25 46 10 83
Dako Denmark A/S
maia.sochting@dako.com

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Dako Denmark A/S via Thomson Reuters ONE
HUG#1677383